Cargando…

Safety and Efficacy of Elobixibat, an Ileal Bile Acid Transporter Inhibitor, in Elderly Patients With Chronic Idiopathic Constipation According to Administration Time: Interim Analysis of Post-marketing Surveillance

BACKGROUND/AIMS: Elobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of post-marketing surveillance to evaluate the safety and effic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakajima, Atsushi, Fujimaki, Mio, Arai, Yuki, Emori, Kento
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Society of Neurogastroenterology and Motility 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274463/ https://www.ncbi.nlm.nih.gov/pubmed/35799237 http://dx.doi.org/10.5056/jnm20263

Ejemplares similares

Impact of elobixibat on serum and fecal bile acid levels and constipation symptoms in patients with chronic constipation
por: Nakajima, Atsushi, et al.
Publicado: (2022)

Effect of single and multiple doses of elobixibat, an ileal bile acid transporter inhibitor, on chronic constipation: A randomized controlled trial
por: Kumagai, Yuji, et al.
Publicado: (2018)

Determining an optimal clinical dose of elobixibat, a novel inhibitor of the ileal bile acid transporter, in Japanese patients with chronic constipation: a phase II, multicenter, double-blind, placebo-controlled randomized clinical trial
por: Nakajima, Atsushi, et al.
Publicado: (2017)

Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
por: Ozaki, Anna, et al.
Publicado: (2021)

Investigating the efficacy and safety of elobixibat, an ileal bile acid transporter inhibitor, in patients with Parkinson’s disease with chronic constipation: a multicentre, placebo-controlled, randomised, double-blind, parallel-group study (CONST-PD)
por: Hatano, Taku, et al.
Publicado: (2022)

Elobixibat alleviates chronic constipation in hemodialysis patients: a questionnaire-based study
por: Kamei, Daigo, et al.
Publicado: (2020)

The Efficacy and Safety of Elobixibat for the Elderly with Chronic Constipation: A Multicenter Retrospective Cohort Study
por: Tomie, Akira, et al.
Publicado: (2020)

Efficacy, long‐term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Efficacy and Safety of Elobixibat in Elderly Patients with Chronic Constipation: A Single-center, Observational Study
por: Abe, Tatsuya, et al.
Publicado: (2020)

Effects of Elobixibat on Constipation and Lipid Metabolism in Patients With Moderate to End-Stage Chronic Kidney Disease
por: Matsuyama, Momoko, et al.
Publicado: (2022)

Correction to: Elobixibat Effectively Relieves Chronic Constipation in Patients with Cancer Regardless of the Amount of Food Intake
Publicado: (2023)

Rationale and design of a multicenter, single-group, open-label trial aiming at investigating the effectiveness of elobixibat for loss of defecation desire in patients with chronic constipation
por: Yamamoto, Atsushi, et al.
Publicado: (2022)

Combined, elobixibat, and colestyramine reduced cholesterol toxicity in a mouse model of metabolic dysfunction-associated steatotic liver disease
por: Iwaki, Michihiro, et al.
Publicado: (2023)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018)

Uncontrolled, Open-Label Pre-Dinner Administration of Elobixibat in Japanese Adults with Chronic Constipation: A Retrospective Chart Review
por: Odaka, Takeo, et al.
Publicado: (2020)

Effects of Elobixibat in Patients with Diabetes and Concomitant Chronic Constipation: an 8-week, Prospective, Single-center, Single-arm Study
por: Hishida, Yoshiaki, et al.
Publicado: (2022)

Elobixibat improves rectal sensation in patients with chronic constipation aged ≥60 years: a randomised placebo-controlled study
por: Manabe, Noriaki, et al.
Publicado: (2023)

Rationale and design of a multicentre, 12-week, randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated trial to investigate the efficacy and safety of elobixibat for chronic constipation
por: Tanaka, Kosuke, et al.
Publicado: (2022)

Treatment of Chronic Constipation using Elobixibat in a Real-World Setting: A Retrospective Cohort Study using an Electronic Medical Records Database in Japan
por: Masaki, Hisanori, et al.
Publicado: (2023)

Efficacy of elobixibat as bowel preparation agent for colonoscopy: Prospective, randomized, multi‐center study
por: Yamaguchi, Daisuke, et al.
Publicado: (2021)

Real-World Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Interim Report of a Post-Marketing Surveillance in Japan
por: Ogura, Takashi, et al.
Publicado: (2023)

A Systematic Review and Network Meta-Analysis on the Efficacy of Medications in the Treatment of Chronic Idiopathic Constipation in Japan
por: Nakajima, Atsushi, et al.
Publicado: (2021)

Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease
por: Kessoku, Takaomi, et al.
Publicado: (2020)

Properties and biological significance of the ileal bile salt transport system.
por: Lack, L
Publicado: (1979)

Relationship between the gut microbiota and bile acid composition in the ileal mucosa of Crohn’s disease
por: Bamba, Shigeki, et al.
Publicado: (2022)

Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan
por: Saida, Takahiko, et al.
Publicado: (2017)

Safety and effectiveness of ustekinumab in Crohn's disease: Interim results of post‐marketing surveillance in Japan
por: Yokoyama, Seiji, et al.
Publicado: (2021)

Jejunal atresia associated with idiopathic ileal perforation
por: Das, P. C., et al.
Publicado: (2008)

Idiopathic Ileal Ulceration After Intestinal Transplantation
por: Hussan, Elsadig, et al.
Publicado: (2023)

A 3-year postmarketing study on the safety and effectiveness of once-monthly risedronate in Japanese patients with osteoporosis
por: Soen, Satoshi, et al.
Publicado: (2020)

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
por: Patel, Sarah, et al.
Publicado: (2021)

Ileal mucosal bile acid absorption is increased in Cftr knockout mice
por: Stelzner, Matthias, et al.
Publicado: (2001)

Associations between Ileal Juice Bile Acids and Colorectal Advanced Adenoma
por: Luu, Hung N., et al.
Publicado: (2023)

Effect of Biofeedback Therapy in Constipation According to Rectal Sensation
por: Ahn, Ji Yong, et al.
Publicado: (2013)

A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation
por: Chey, William D, et al.
Publicado: (2011)

The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation
por: Pennington, Becky, et al.
Publicado: (2018)

Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance
por: Murai, Hiroyuki, et al.
Publicado: (2021)

Safety and Effectiveness Analysis of Dolutegravir in Patients with HIV-1: Interim Report of Post-Marketing Surveillance in Japan
por: Hongo, Haruyuki, et al.
Publicado: (2021)

Enhanced Microbial Bile Acid Deconjugation and Impaired Ileal Uptake in Pregnancy Repress Intestinal Regulation of Bile Acid Synthesis
por: Ovadia, Caroline, et al.
Publicado: (2019)

Corrigendum: A Randomized Placebo-Controlled Phase IIb Trial of A3309, A Bile Acid Transporter Inhibitor, for Chronic Idiopathic Constipation
por: Chey, William D, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bcp6e5dg7pjb0g0b7uf9tukb47